Gore Receives FDA Approval for 25 cm Gore Viabahn Endoprosthesis

Longest stent-graft introduced in the United States


January 28, 2014
Gore Viabahn Endoprosthesis Heparin Bioactive Surface Stent Grafts Aneurism

W. L. Gore & Associates’ 25 cm Gore Viabahn Endoprosthesis with Heparin Bioactive Surface for the treatment of symptomatic peripheral arterial disease (PAD) lesions in the Superficial Femoral Artery (SFA). The 25 cm endoprosthesis is designed to cover long-segment lesions in the SFA, potentially reducing the need for multiple devices. The stent-graft design of the Gore Viabahn Endoprosthesis with Heparin Bioactive Surface consists of a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure that acts as a barrier to in-stent restenosis. The device is available in configurations that are compatible with 0.035 in or 0.018/0.014 in wire platforms. The device also incorporates the Heparin Bioactive Surface, which utilizes a proprietary end-point covalent immobilization of heparin to the surface of the endoprosthesis. This proprietary surface technology is intended to provide a thromboresistant surface through sustained heparin bioactivity. The U.S. Food and Drug Administration (FDA) approved the Gore Viabahn device in January 2014. For more information: www.goremedical.com